Company: ZVRA
Filing Date: 2025-04-10
Form Type: PREC14A
Source: 0000897069-25-000784
Chunk: 0

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-10
Form: PREC14A
Chunk 0
---
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 _____________________________________ SCHEDULE 14A (RULE 14a-101)
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(AMENDMENT NO. ) _____________________________________

| Filed by the Registrant ☐ | Filed by a Party other than the Registrant ☒ |

Check the appropriate box:

| ☒                                                | Preliminary Proxy Statement                                                     |
| ☐                                                | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐                                                | Definitive Proxy Statement                                                      |
| ☐                                                | Definitive Additional Materials                                                 |
| ☐                                                | Soliciting Material Under Rule 14a-12                                           |
| Zevra Therapeutics, Inc.                         |                                                                                 |
| (Name of registrant as specified in its charter) |                                                                                 |

DANIEL J. MANGLESS
TRAVIS C. MICKLE, PhD
ARTHUR C. REGAN
(Name of Person(s) Filing Proxy Statement, if other than the Registrant) -with copies to- Peter D. Fetzer Foley & Lardner LLP 777 East Wisconsin Avenue Milwaukee, WI 53202-5306 (414) 297-5596 Payment of Filing Fee (Check all boxes that apply):

| ☒ | No fee required                                                                                     |
| ☐ | Fee paid previously with preliminary materials                                                      |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION, DATED APRIL 10, 2025 2025 ANNUAL MEETING OF STOCKHOLDERS OF ZEVRA THERAPEUTICS, INC. PROXY STATEMENT OF DANIEL J. MANGLESS
TRAVIS C. MICKLE, PhD
ARTHUR C. REGAN [●], 2025 To Our Fellow Stockholders of Zevra Therapeutics, Inc.: This Proxy Statement is furnished to holders of the common stock, par value $0.0001 per share (“ Common Stock”), of Zevra Therapeutics, Inc. (“ Zevra” or the “ Company”), located at 1180 Celebration Boulevard, Suite 103